Post-Marketing Study Of The Safety Of Tygacil (Tigecycline)

Pfizer

Status: Completed

Conditions: Complicated Skin and Skin Structure Infections; Complicated Intra-abdominal Infections

Treatments: Drug: Tigecycline (Tygacil)

Study type: Observational

Funder types: Industry

Identifiers

NCT00683332

B1811057

3074A1-102235

Details and patient eligibility

About

The purpose of this study is to collect post-marketing information on the safety of Tygacil in Filipino patients.

Full description

Three-thousand or 10% of total number of patients given tigecycline will be included in the study

Enrollment: 621 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients from the study center who received or will receive at least one dose of Tygacil according to the approved product indication.

Exclusion criteria

• Previously discontinued Tygacil therapy due to significant safety concern.

Trial design

621 participants in 1 patient group

A

Treatment:

Drug: Tigecycline (Tygacil)